NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









InEdita Bio

InEdita Bio

Private
United StatesHealthcare & Life Scienceshttps://www.ineditabio.com/

Last Round

Grant

Aug 4, 2025

Momentum

Top 50%

of companies Caplight tracks

Company Overview

InEdita Bio is an agricultural biotechnology company that develops a proprietary genome editing platform using CRISPR technology to create non-transgenic crops with enhanced resistance to pests, diseases, and environmental stressors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

genome editingagtechgene silencingnon-transgenic cropsclimate-resilient cropsbiotechnologytrait developmentCRISPRseed technologybioinformaticsgene expressionagricultural innovationsynthetic biologyIP licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

InEdita Bio Comparables

Compare InEdita Bio with similar companies based on industry and business-model similarity.

InEdita Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cibus, Inc.
83%
Phytoform Labs
83%
Hudson River Biotechnology
82%

InEdita Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantAug 4, 2025
SeedAug 20, 2023

InEdita Bio Investors

Notable investors and investment history

InEdita Bio investors
InvestorRounds
Financiadora de Estudos e ProjetosGrant
Ecoa CapitalSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 4, 2025

    Received grant funding from Financiadora de Estudos e Projetos.

  • Jun 8, 2025

    Grew 50% QoQ from 6 to 9 employees.

InEdita Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

InEdita Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about InEdita Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersUnited States
Employee Range12
Year Founded2022
Last FundingAug 4, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.